MacroGenics axes ADC drug following Phase II failure in prostate cancer

Submitted by admin on March 25, 2025 - 10:27am

Source:

Clinical Trials Arena

News Tags:

Headline:

snippet:

MacroGenics is axing the development of one of its antibody-drug conjugates (ADC) after it flopped in a Phase II study in prostate cancer.

Search form